Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, announced that the U.S. Patent and Trademark Office (USPTO) has granted the patent application for Clarity’s SAR-bisPSMA compound and its variants. The grant of the patent application bolsters Clarity’s strong Intellectual Property (IP) position on the Prostate Specific Membrane Antigen (PSMA) targeting agent for imaging and the treatment of prostate cancer.

SAR-bisPSMA is the result of Clarity’s optimization of the well characterized PSMA targeting peptide, which has been in many thousands of patients to date, by combining two PSMA targeting peptides with Clarity’s proprietary SAR Technology and the theragnostic isotopes of copper, copper-64 for imaging and copper-67 for therapy. The copper pairing enables diagnosis, staging and subsequent treatment of prostate cancers that express PSMA. The optimization of the targeting peptide has resulted in superior targeting of, and retention in, tumors compared to a singular PSMA targeting peptide in preclinical models. The product was developed through the long-standing collaboration between Clarity and Professor Paul Donnelly at the University of Melbourne.

To read more please visit:

https://www.claritypharmaceuticals.com/news/sar-bispsma-patent/

Source: Clarity Pharmaceuticals